| Univariate analysis | Multivariate analysis* | Odds ratio (95% confidence interval) |
---|---|---|---|
Age (years) | < 0.001 | N.S. | Â |
Sex (male/female) | 0.005 | N.S. | Â |
BMI, median (range) | N.S. | Â | Â |
Prior treatment for HCV (no/yes) | N.S. | Â | Â |
Pretreatment HCV RNA levels (log10 IU/mL), (≤6.0 vs. 6.0<) | 0.015 | 0.013 | 2.235 (1.189-4.203) |
Platelet count (×103/μL) | < 0.001 | 0.011 | 1.007 (1.002-1.013) |
Hemoglobin (g/dL) | 0.002 | N.S. | Â |
Neutrophil count (/μL) | 0.003 | N.S. |  |
Alanine aminotransferase (IU/L) | N.S. | Â | Â |
Total-cholesterol (mg/dL) | 0.001 | N.S. | Â |
γ-glutamyl transpeptidase (IU/L) | 0.014 | N.S. |  |
Fibrosis score (F1 or F2/F3 or F4) | < 0.001 | N.S. | Â |
Activity score (A1 or A2/A3 or A4) | 0.002 | N.S. | Â |
Genetic polymorphisms of rs8099917 (TT/GG or TG) | < 0.001 | < 0.001 | 5.782 (2.298-14.552) |
Amino acid at residue 70 of HCV core (arginine/glutamine or histidine) | < 0.001 | N.S. | Â |
Amino acid sequence of ISDR (non-wild-type/wild-type) | < 0.001 | 0.038 | 2.077 (1.041-4.147) |
Reduction of HCV RNA [Pre - 4 week] (log10 IU/mL), (≤2.8 vs. 2.8<) | < 0.001 | < 0.001 | 3.911 (1.935-7.908) |
Reduction of HCV RNA [Pre - 12 week] (log10 IU/mL), (≤4.9 vs. 4.9<) | < 0.001 | 0.013 | 2.578 (1.220-5.448) |